Shigyo2025FPTPC

Title

From Play to Precision Care: Clinical Telegaming Biomarkers to Evaluate Medication Efficacy for Improving Multiple Sclerosis Patients' Quality of Life
View PDF | Save PDF

Authors

Kento Shigyo, Adam Craig, Carl Taswell

Affiliations

Brain Health Alliance Virtual Institute, Ladera Ranch, CA 92694 USA

Abstract

Multiple sclerosis (MS) is a chronic autoimmune disease characterized by progressive deterioration of motor, sensory, cognitive, and social functioning. Its relapsing and heterogeneous nature means that symptom severity and trajectory vary across patients, often leading to long-term declines in independence and quality of life in daily living. Disease-modifying therapies (DMTs) aim to slow this progression and support functional recovery, with efficacy monitored through periodic clinic visits that inform treatment adjustments. While DMTs have demonstrated efficacy in reducing relapse rates and slowing disability progression at the population level, determining which medications are most effective for individual patients remains challenging due to the heterogeneity of MS symptoms and treatment responses. Current clinic-based evaluations provide only infrequent snapshots of patients' functioning, often missing the fatigue, cognitive lapses, and social withdrawal that manifest under the demands of everyday life. Without continuous and timely data on these aspects, clinicians lack the granular evidence needed to detect subtle treatment responses or adjust therapies in a timely manner. To address this problem, we apply the framework of clinical telegaming as a complementary assessment platform that bridges home-based and in-clinic evaluation for individuals living with MS. By delivering structured, interactive games via augmented or mixed-reality displays in everyday environments, the system captures motor-sensory and social-behavioral interaction data to generate digital biomarkers. These biomarkers aim to complement existing clinical assessments, enabling timely and comprehensively evaluation of medication efficacy and quality-of-life outcomes in support of precision care. We expect this approach to yield clinically meaningful digital biomarkers that continuously and individually capture how MS affects patients' daily functioning, providing a richer record of treatment response than clinic visits alone can offer. By bridging in-clinic assessments and everyday functioning, the proposed telegaming telecare system would have the potential to support more informed, timely, and cost-efficient treatment decisions, ultimately contributing to more precise patient-centered MS care.

KeyPhrases

Multiple sclerosis, clinical telegaming, digital biomarkers, precision care, individualized treatment, quality of life.

Dates

Created 2025-09-16, presented 2025-10-09, updated 2025-12-17, published 2025-12-17, revised 2026-06-07.

Citation

Brainiacs Journal 2025 Volume 6 Issue 3 Edoc B3D757EF9
DOI: 10.48085/B3D757EF9
NPDS: LINKS/Brainiacs/Shigyo2025FPTPC

Reviews